IMMIX BIOPHARMA, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
IMMIX BIOPHARMA, INC. (IMMX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.85 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $8.07, a 266.82% increase year-over-year.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.20.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.83.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.63, a 20.09% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.19, a 17.74% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.86, a 31.11% decline from fiscal 2022.
- IMMIX BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.70, a 68.75% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $8.85 10-Q · filed 2026-08-07 | ||||
| 2026-03-31 | $8.07 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $2.63 10-K/A · filed 2026-03-27 | ||||
| 2025-09-30 | $2.24 10-Q · filed 2025-11-07 | ||||
| 2025-06-30 | $2.24 10-Q · filed 2025-08-08 | ||||
| 2025-03-31 | $2.20 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | $2.19 10-K/A · filed 2026-03-27 | ||||
| 2024-09-30 | $2.21 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $2.21 10-Q · filed 2024-08-12 | ||||
| 2023-12-31 | $1.86 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | $1.86 10-Q · filed 2023-11-13 | ||||
| 2022-12-31 | $2.70 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $2.70 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $5.83 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $5.83 10-Q · filed 2022-05-13 | ||||
| 2022-01-13 | $5.83 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $1.60 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |